JPMorgan analyst Eric Joseph lowered the firm’s price target on Relay Therapeutics to $21 from $23 and keeps an Overweight rating on the shares. The analyst updated the company’s model following the interim data for RLY-2608.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target raised to $24 from $20 at BofA
- Relay Therapeutics upgraded to Buy from Hold at Jefferies
- Relay Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Relay Therapeutics reinstated with a Buy at Goldman Sachs
- Relay Therapeutics announces $200M common stock offering
Questions or Comments about the article? Write to editor@tipranks.com